{"id":"hydroxocobalamin-chloride-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, erythema)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Hypokalemia (rare, in severe deficiency)"}]},"_chembl":{"chemblId":"CHEMBL2103737","moleculeType":"Small molecule","molecularWeight":"1346.38"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Hydroxocobalamin is a naturally occurring form of vitamin B12 (cobalamin) that serves as a cofactor for critical enzymatic reactions including methionine synthase and methylmalonyl-CoA mutase. It is used to treat vitamin B12 deficiency states, which can result from pernicious anemia, malabsorption, dietary insufficiency, or other causes. By replenishing intracellular cobalamin stores, it corrects metabolic dysfunction and prevents or reverses neurological complications associated with B12 deficiency.","oneSentence":"Hydroxocobalamin chloride is a form of vitamin B12 that replaces deficient cobalamin and restores normal cellular metabolism and neurological function.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:55:04.066Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Vitamin B12 deficiency"},{"name":"Pernicious anemia"},{"name":"B12 deficiency-related neurological complications"}]},"trialDetails":[{"nctId":"NCT05751187","phase":"PHASE2","title":"Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2023-06-27","conditions":"Non-squamous NSCLC","enrollment":54},{"nctId":"NCT02662504","phase":"PHASE2","title":"Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2016-01-16","conditions":"Malignant Pleural Mesothelioma","enrollment":6},{"nctId":"NCT07163364","phase":"PHASE3","title":"A Study to Evaluate the Effects and Safety of Hydroxocobalamin in Participants With Combined Methylmalonic Academia (cblC Type)","status":"NOT_YET_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2025-08-31","conditions":"Methylmalonic Acidemia (MMA)","enrollment":20},{"nctId":"NCT04786964","phase":"PHASE3","title":"Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC","status":"TERMINATED","sponsor":"Checkpoint Therapeutics, Inc.","startDate":"2021-12-08","conditions":"Metastatic Non-squamous Non Small Cell Lung Cancer","enrollment":25},{"nctId":"NCT06749756","phase":"NA","title":"Study on the Improvement of Microcirculation in Patients With Sepsis by Vitamin B6, Vitamin B12 and Vitamin C","status":"RECRUITING","sponsor":"Fan Zeng","startDate":"2025-02-10","conditions":"Septic Shock","enrollment":296},{"nctId":"NCT02578680","phase":"PHASE3","title":"Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-01-15","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":616},{"nctId":"NCT03950674","phase":"PHASE3","title":"Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-02-22","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":40},{"nctId":"NCT04708340","phase":"PHASE1, PHASE2","title":"Tolerability and Efficacy of RJX in Patients With COVID-19","status":"UNKNOWN","sponsor":"Reven Pharmaceuticals, Inc.","startDate":"2021-03-25","conditions":"COVID-19, Acute Respiratory Distress Syndrome, SARS-CoV-2","enrollment":237},{"nctId":"NCT01420679","phase":"PHASE3","title":"Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients","status":"TERMINATED","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2011-08","conditions":"Peripheral T-cell Lymphoma","enrollment":21},{"nctId":"NCT00606502","phase":"PHASE2","title":"Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment","status":"COMPLETED","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2008-01","conditions":"Non-small Cell Lung Cancer","enrollment":201},{"nctId":"NCT00481871","phase":"PHASE1, PHASE2","title":"Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies","status":"COMPLETED","sponsor":"Acrotech Biopharma Inc.","startDate":"2007-05","conditions":"Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma, Peripheral T-cell Lymphoma","enrollment":119},{"nctId":"NCT00554827","phase":"PHASE1","title":"Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma","status":"COMPLETED","sponsor":"Acrotech Biopharma Inc.","startDate":"2007-08","conditions":"Cutaneous T-cell Lymphoma","enrollment":55},{"nctId":"NCT01134341","phase":"PHASE1","title":"Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma","status":"COMPLETED","sponsor":"Acrotech Biopharma Inc.","startDate":"2010-03","conditions":"Cutaneous T-cell Lymphoma, Mycosis Fungoides, Sezary Syndrome","enrollment":34},{"nctId":"NCT00722553","phase":"PHASE2","title":"Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder","status":"COMPLETED","sponsor":"Acrotech Biopharma Inc.","startDate":"2008-07","conditions":"Carcinoma, Transitional Cell, Bladder Cancer, Bladder Neoplasm","enrollment":30},{"nctId":"NCT01165021","phase":"PHASE2","title":"A Study of Pemetrexed/Cisplatin as Pre-operative Treatment of Early Stage Nonsquamous Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-11","conditions":"Non Small Cell Lung Cancer","enrollment":19},{"nctId":"NCT02919462","phase":"PHASE2","title":"Open-label, Multicenter, Randomized Phase II Trial of Treatment With Cisplatin and Pemetrexed or Cisplatin and Oral Vinorelbine in Chemotherapy Naïve Patients Affected by Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer With High Thymidylate Synthase Expression","status":"TERMINATED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2016-03","conditions":"Carcinoma, Non-Small-Cell Lung, Secondary, Advanced Stage IIIB","enrollment":2},{"nctId":"NCT01194453","phase":"PHASE2","title":"Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced NSCLC Metastatic Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2009-11","conditions":"Non-small Cell Lung Cancer, Efficacy","enrollment":288},{"nctId":"NCT00659269","phase":"PHASE3","title":"A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients","status":"COMPLETED","sponsor":"New Mexico Cancer Research Alliance","startDate":"2006-07","conditions":"Cancer","enrollment":319},{"nctId":"NCT01204307","phase":"PHASE2","title":"Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2010-01","conditions":"Advanced Non-Squamous Non-Small Cell Lung Cancer","enrollment":101},{"nctId":"NCT01057589","phase":"PHASE2","title":"A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-02","conditions":"Head and Neck Neoplasms","enrollment":66},{"nctId":"NCT01569919","phase":"PHASE2","title":"A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural Mesothelioma","status":"UNKNOWN","sponsor":"Wales Cancer Trials Unit","startDate":"2012-12","conditions":"Malignant, Pleural, Mesothelioma","enrollment":26},{"nctId":"NCT00744900","phase":"PHASE2","title":"Pemetrexed Plus Cisplatin for Brain Metastasis of Advanced Non - Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"University Hospital, Brest","startDate":"2008-09","conditions":"Lung Cancer","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Hydroxocobalamin Chloride Injection","genericName":"Hydroxocobalamin Chloride Injection","companyName":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","companyId":"cspc-zhongqi-pharmaceutical-technology-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hydroxocobalamin chloride is a form of vitamin B12 that replaces deficient cobalamin and restores normal cellular metabolism and neurological function. Used for Vitamin B12 deficiency, Pernicious anemia, B12 deficiency-related neurological complications.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}